Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSL ( (AU:CSL) ) just unveiled an update.
CSL Limited announced its financial results for the year ending June 30, 2025, reporting a 5% increase in total revenue to US$15.558 billion and a 14% rise in net profit after tax (NPAT) to US$3.002 billion. The company also declared an unfranked final dividend of US$1.62 per share. These results reflect CSL’s strong performance and growth in the biotechnology sector, positioning it well for future advancements and stakeholder confidence.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$325.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a global biotechnology company based in Melbourne, Australia, specializing in the development and delivery of innovative medicines and therapies. The company focuses on providing solutions for rare and serious diseases, particularly in the areas of immunology, hematology, and respiratory health.
YTD Price Performance: -3.21%
Average Trading Volume: 743,260
Technical Sentiment Signal: Buy
Current Market Cap: A$130.9B
For an in-depth examination of CSL stock, go to TipRanks’ Overview page.